Clinical trials: NSCLC Stage II
Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer
Dasatinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This phase II trial is studying how well dasatinib works in treating patients with stage IIIB, stage IV, or recurrent non-small…
- Conditions
- Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT00459342
- Testing
- dasatinib
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Non-Small Cell Lung Cancer
Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)
This trial will investigate the use of the newer targeted agents erlotinib and sorafenib in patients with stage IIIB or stage IV NSCLC who have received 1-2 prior chemotherapy regimens.
- Trial name
- NCT00600015
- Testing
- Erlotinib + Sorafenib
- Where
- 16 sites in United States
- Volunteers
- 166 people
- Sponsor
- SCRI Development Innovations, LLC
Non-Small Cell Lung Cancer
Phase II Single Arm Study of AZD9291 to Treat NSCLC Patients in Asia Pacific
A Phase II, Open Label, Single-arm Study to Assess the Safety and Efficacy of AZD9291 in Asia Pacific Patients with Locally Advanced/Metastatic Non-Small Cell Lung Cancer whose Disease has Progressed with Previous Epidermal…
- Trial name
- AURA17 (NCT02442349)
- Testing
- AZD9291
- Where
- 30 sites in Australia, China and 1 more
- Volunteers
- 171 people
- Sponsor
- AstraZeneca
Carcinoma, Non-Small-Cell Lung
Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC
This is a research study to test the effectiveness of nab-paclitaxel + carboplatin + MPDL3280A for treatment of non-small-cell lung carcinoma (NSCLC), which is a type of lung cancer.
- Trial name
- NCT02716038
- Testing
- MPDL3280A, Carboplatin, Nab-paclitaxel
- Where
- 3 sites in United States
- Volunteers
- 39 people
- Sponsor
- Columbia University
Lung Cancer, Metastatic Cancer
Cryotherapy in Treating Patients With Primary Lung Cancer or Lung Metastases That Cannot Be Removed By Surgery
RATIONALE: Cryotherapy kills tumor cells by freezing them. This may be an effective treatment for primary lung cancer or lung metastases that cannot be removed by surgery.
- Trial name
- NCT00303901
- Testing
- cryosurgery, positron emission tomography
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Lung Cancer
Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC
This research study is studying a drug intervention as a possible treatment for lung cancer. The drugs involved in this study are: Nivolumab Carboplatin Pemetrexed Ipilimumab
- Trial name
- NCT03256136
- Testing
- Carboplatin, Nivolumab, pemetrexed
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- Massachusetts General Hospital
Bronchioloalveolar Carcinoma, Large Cell Lung Carcinoma
Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer
This randomized phase II trial studies how well pemetrexed disodium with or without erlotinib hydrochloride works in treating patients with stage IIIB-IV or recurrent non-small cell lung cancer.
- Conditions
- Bronchioloalveolar Carcinoma, Large Cell Lung Carcinoma, Lung Adenocarcinoma, Recurrent Non-Small Cell Lung Carcinoma
- Trial name
- NCT00950365
- Testing
- Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Pemetrexed Disodium
- Where
- 5 sites in United States
- Volunteers
- 79 people
- Sponsor
- Albert Einstein College of Medicine
Oligometastatic Non-small Cell Lung Cancer (NSCLC)
Phase II Study of Pembrolizumab After Curative Intent Treatment for Oligometastatic Non-Small Cell Lung Cancer
The main purpose of this study is to see how well the experimental drug pembrolizumab (MK-3475) works in people with oligometastatic NSCLC who have already had treatment for their disease.
- Trial name
- NCT02316002
- Testing
- Pembrolizumab
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Stage IIB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7
FLARE RT for Patients With Stage IIB-IIIB Non-small Cell Lung Cancer: Personalizing Radiation Therapy Using PET/CT and SPECT/CT Imaging
This phase II trial studies how well positron emission tomography (PET)/computed tomography (CT) and single positron emission computed tomography (SPECT)/CT imaging works in improving radiation therapy treatment in patients with…
- Conditions
- Stage IIB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7
- Trial name
- NCT02773238
- Testing
- Computed Tomography, Fludeoxyglucose F-18, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 51 people
- Sponsor
- University of Washington
Recurrent Non-small Cell Lung Cancer
AZD2171 in Treating Patients With Recurrent Small Cell Lung Cancer
This phase II trial is studying how well AZD2171 works in treating patients with recurrent small cell lung cancer. AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking…
- Trial name
- NCT00245063
- Testing
- cediranib maleate, laboratory biomarker analysis, pharmacogenomic studies
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Non-Small Cell Lung Cancer
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
This multicenter, single-arm study will evaluate the efficacy and safety of atezolizumab (MPDL3280A) in participants with PD-L1-positive locally advanced or metastatic NSCLC.
- Trial name
- NCT01846416
- Testing
- Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody
- Where
- 31 sites in United States, Belgium and 3 more
- Volunteers
- 138 people
- Sponsor
- Genentech, Inc.
Non Small Cell Lung Cancer (NSCLC)
Study of Cetuximab With Radiation Followed by Consolidation Chemotherapy for NSCLC
This is an open label, phase II study in which cetuximab with concurrent thoracic radiotherapy followed by consolidation chemotherapy with paclitaxel/carboplatin/cetuximab will be administered to subjects with locally advanced…
- Trial name
- NCT00492206
- Testing
- Cetuximab
- Where
- 31 sites in United States
- Volunteers
- 40 people
- Sponsor
- University of Pittsburgh
Stage III Non-small-cell Lung Cancer
Chemoradiation Followed by Durvalumab in Poor Risk and/or Elderly Patients With Stage III NSCLC
Elderly (age 70 years or older) or >18 years old AND poor risk (ECOG 2) newly diagnosed stage IIIA-C (AJCC 8th edition) inoperable non-small cell lung cancer (NSCLC) patients are eligible to participate in this phase II open…
- Trial name
- ESR1814205 (NCT04441138)
- Testing
- Durvalumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Rush University Medical Center
Non-Squamous Non-Small Cell Lung Cancer
A Study of Tarceva (Erlotinib) in Patients With Locally Advanced, Metastatic or Recurrent Non-Small Cell Cancer Who Present Epidermal Growth Factor Receptor Mutations
This open-label study will assess the efficacy and safety of Tarceva (Erlotinib) in patients with locally advanced, metastatic or recurrent non-small cell lung cancer who have not received previous chemotherapy for their disease…
- Trial name
- NCT01372384
- Testing
- erlotinib [Tarceva]
- Where
- 9 sites in Bulgaria
- Volunteers
- 6 people
- Sponsor
- Hoffmann-La Roche
Cancer
Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.
This was a Phase II, multicenter, non-randomized, open-label study to assess the efficacy, safety, and tolerability of dabrafenib administered as a single agent and in combination with trametinib in stage IV disease to subjects…
- Trial name
- NCT01336634
- Testing
- Dabrafenib, Trametinib
- Where
- 50 sites in United States, France and 9 more
- Volunteers
- 177 people
- Sponsor
- Novartis Pharmaceuticals
Non-Small Cell Lung Cancer
A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This multicenter, single-arm study will evaluate the efficacy and safety of Atezolizumab in participants with PD-L1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).
- Trial name
- BIRCH (NCT02031458)
- Testing
- Atezolizumab
- Where
- 110 sites in United States, Australia and 17 more
- Volunteers
- 667 people
- Sponsor
- Hoffmann-La Roche
Lung Cancer
S0526: Pemetrexed Disodium in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as pemetrexed disodium, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00265785
- Testing
- pemetrexed
- Where
- 112 sites in United States
- Volunteers
- 27 people
- Sponsor
- SWOG Cancer Research Network
Lung Cancer
Iressa Re-Challenge in Advanced NSCLC EGFR M+ Patients Who Responded to Gefitinib USed as 1st Line or Previous Treatment
the primary objective is to characterise the impact of gefitinib on the Response Evaluation Criteria in Solid Tumours (RECIST) based assessments; objective response rate (ORR ; confirmed complete response(CR) or partial response…
- Trial name
- ICARUS (NCT01530334)
- Testing
- Gefitinib 250mg
- Where
- 24 sites in Italy
- Volunteers
- 61 people
- Sponsor
- AstraZeneca
Carcinoma, Non-Small-Cell Lung
Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC
This is an open label, multi-institutional, single arm phase II trial of consolidation therapy with pembrolizumab, following initial treatment with concurrent chemoradiation in patients with inoperable or unresectable stage IIIA…
- Trial name
- NCT02343952
- Testing
- Pembrolizumab
- Where
- 15 sites in United States
- Volunteers
- 93 people
- Sponsor
- Nasser Hanna, M.D.
Non Small Cell Lung Cancer
GW786034 in Patients With Non Small Cell Lung Cancer 3rd Line
Lung Cancer is the most common cause of cancer death in the United States with an estimated mortality in excess of 160,000, more than the combined mortality seen with prostate, breast, colorectal cancers(1).
- Trial name
- NCT01049776
- Testing
- Pazopanib (GW786034)
- Where
- 13 sites in United States
- Volunteers
- 32 people
- Sponsor
- Illinois CancerCare, P.C.